As of June 8, 2025, China Isotope & Radiation Corp (1763.HK) reports a Net Margin of 5.37%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of China Isotope & Radiation Corp's Net Margin
Over recent years, China Isotope & Radiation Corp's Net Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | 5.37% |
| 2023-12-31 | 5.59% |
| 2022-12-31 | 6.37% |
| 2021-12-31 | 6.53% |
| 2020-12-31 | 5.00% |
This gradual decrease highlights how China Isotope & Radiation Corp manages its overall profitability and cost control over time.
Comparing China Isotope & Radiation Corp's Net Margin to Peers
To better understand China Isotope & Radiation Corp's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| China Isotope & Radiation Corp (1763.HK) | 5.37% |
| Kangji Medical Holdings Ltd (9997.HK) | 57.65% |
| Beijing Succeeder Technology Inc (688338.SS) | 42.44% |
| Shanghai MicroPort Endovascular MedTech Group Co Ltd (688016.SS) | 41.62% |
| Yestar Healthcare Holdings Co Ltd (2393.HK) | 38.24% |
| Autek China Inc (300595.SZ) | 31.55% |
Compared to its competitors, China Isotope & Radiation Corp's Net Margin is among the lowest compared to peers, which may indicate challenges in controlling expenses or competitive pricing pressures.